We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Globus Medical (GMED) Q2 Earnings In Line, Revenue View Up
Read MoreHide Full Article
Globus Medical, Inc. (GMED - Free Report) reported second-quarter 2019 adjusted earnings per share (EPS) of 41 cents, in line with the Zacks Consensus Estimate. Meanwhile, the metric missed the year-ago figure by 6.8%.
On a reported basis, the company registered earnings of 38 cents per share, reflecting a 13.6% decline from the year-ago quarter.
Revenue Details
Second-quarter 2019 worldwide sales summed $194.5 million, up 12.2% (up 12.7% at constant exchange rate or CER) year over year. The figure also exceeded the Zacks Consensus Estimate by 5.9%.
During the quarter under review, sales generated in the United States including robotic improved 10% year over year. However, quarterly seasonality and longer sales cycles partially dampened robotic sales in the reported period.
Globus Medical, Inc. Price, Consensus and EPS Surprise
Meanwhile, international sales rose 23.3% from the year-earlier quarter (up 26.7% at CER).
Moreover, musculoskeletal solutions products generated revenues of $182.5 million, up 14.3% year over year. However, Enabling Technologies products revenues of $12 million in the quarter represented a 12.7% decline from the prior-year period.
Cash Position
Globus Medical exited the second quarter with cash and cash equivalents and short-term marketable securities of $240.4 million compared with $320.7 million at the end of the first quarter. Year to date, net cash provided by the operating activities was $61.8 million compared with $85.6 million a year ago.
2019 Guidance Updated
The company reaffirmed its 2019 adjusted EPS guidance at $1.72, matching the current Zacks Consensus Estimate for the metric.
However, 2019 sales guidance has been raised to $775 million from $770 million predicted earlier. The Zacks Consensus Estimate for revenues is pegged at $767.5 million, lower than the company’s projection.
Our Take
Globus Medical posted a mixed second-quarter performance with earnings meeting the Zacks Consensus Estimate while revenues beating the mark. Enabling Technologies registered strong sequential growth. Also, global spine business demonstrated a strong year-over-year improvement. An upped sales outlook for 2019 is indicative of this bullish trend to continue through the remaining year.
Zacks Rank & Key Picks
Globus Medical carries a Zacks Rank #4 (Sell).
Some better-ranked stocks having reported solid results this earnings season are Stryker Corporation (SYK - Free Report) , Baxter International Inc. (BAX - Free Report) and Intuitive Surgical, Inc. (ISRG - Free Report) .
Stryker delivered second-quarter 2019 adjusted earnings per share of $1.98, topping the Zacks Consensus Estimate by 2.6%. Further, revenues of $3.65 billion surpassed the Zacks Consensus Estimate by 1.4%. The company carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Baxter delivered second-quarter 2019 adjusted earnings of 89 cents per share, which surpassed the Zacks Consensus Estimate of 81 cents by 9.9%. Additionally, revenues of $2.84 billion outpaced the Zacks Consensus Estimate of $2.79 billion by 1.9%. The company has a Zacks Rank of 2.
Intuitive Surgical reported second-quarter 2019 adjusted earnings per share of $3.25, which exceeded the Zacks Consensus Estimate of $2.85. Also, revenues of $1.1 billion came ahead of the Zacks Consensus Estimate of $1.03 billion. The company sports a Zacks Rank #1.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Globus Medical (GMED) Q2 Earnings In Line, Revenue View Up
Globus Medical, Inc. (GMED - Free Report) reported second-quarter 2019 adjusted earnings per share (EPS) of 41 cents, in line with the Zacks Consensus Estimate. Meanwhile, the metric missed the year-ago figure by 6.8%.
On a reported basis, the company registered earnings of 38 cents per share, reflecting a 13.6% decline from the year-ago quarter.
Revenue Details
Second-quarter 2019 worldwide sales summed $194.5 million, up 12.2% (up 12.7% at constant exchange rate or CER) year over year. The figure also exceeded the Zacks Consensus Estimate by 5.9%.
During the quarter under review, sales generated in the United States including robotic improved 10% year over year. However, quarterly seasonality and longer sales cycles partially dampened robotic sales in the reported period.
Globus Medical, Inc. Price, Consensus and EPS Surprise
Globus Medical, Inc. price-consensus-eps-surprise-chart | Globus Medical, Inc. Quote
Meanwhile, international sales rose 23.3% from the year-earlier quarter (up 26.7% at CER).
Moreover, musculoskeletal solutions products generated revenues of $182.5 million, up 14.3% year over year. However, Enabling Technologies products revenues of $12 million in the quarter represented a 12.7% decline from the prior-year period.
Cash Position
Globus Medical exited the second quarter with cash and cash equivalents and short-term marketable securities of $240.4 million compared with $320.7 million at the end of the first quarter. Year to date, net cash provided by the operating activities was $61.8 million compared with $85.6 million a year ago.
2019 Guidance Updated
The company reaffirmed its 2019 adjusted EPS guidance at $1.72, matching the current Zacks Consensus Estimate for the metric.
However, 2019 sales guidance has been raised to $775 million from $770 million predicted earlier. The Zacks Consensus Estimate for revenues is pegged at $767.5 million, lower than the company’s projection.
Our Take
Globus Medical posted a mixed second-quarter performance with earnings meeting the Zacks Consensus Estimate while revenues beating the mark. Enabling Technologies registered strong sequential growth. Also, global spine business demonstrated a strong year-over-year improvement. An upped sales outlook for 2019 is indicative of this bullish trend to continue through the remaining year.
Zacks Rank & Key Picks
Globus Medical carries a Zacks Rank #4 (Sell).
Some better-ranked stocks having reported solid results this earnings season are Stryker Corporation (SYK - Free Report) , Baxter International Inc. (BAX - Free Report) and Intuitive Surgical, Inc. (ISRG - Free Report) .
Stryker delivered second-quarter 2019 adjusted earnings per share of $1.98, topping the Zacks Consensus Estimate by 2.6%. Further, revenues of $3.65 billion surpassed the Zacks Consensus Estimate by 1.4%. The company carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Baxter delivered second-quarter 2019 adjusted earnings of 89 cents per share, which surpassed the Zacks Consensus Estimate of 81 cents by 9.9%. Additionally, revenues of $2.84 billion outpaced the Zacks Consensus Estimate of $2.79 billion by 1.9%. The company has a Zacks Rank of 2.
Intuitive Surgical reported second-quarter 2019 adjusted earnings per share of $3.25, which exceeded the Zacks Consensus Estimate of $2.85. Also, revenues of $1.1 billion came ahead of the Zacks Consensus Estimate of $1.03 billion. The company sports a Zacks Rank #1.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>